Phase 2
Completed N=24
The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Source: ClinicalTrials.gov NCT00893074 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Aug 2017
Primary outcomePrimary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Summary
A subset of heavy marijuana users have trouble quitting marijuana use and the number of those seeking treatment for problems related to marijuana is increasing. The purpose of this research study is to investigate whether dronabinol can reduce withdrawal effects associated with stopping marijuana use, if dronabinol can reduce the rewarding effects of smoked marijuana, and whether there are any cognitive performance deficits associated with dronabinol doses that produce such effects.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Peak Effect of Marijuana Withdrawal |
4.6; 4.1; 2.9; 1.7 | — |
| PRIMARY Subjective "Drug Effect" After Smoked Marijuana |
23; 28; 24; 29 | — |
| SECONDARY Heart Rate |
88; 85; 80; 76 | — |
Eligibility Criteria
Inclusion Criteria
- current use of marijuana
- able to give informed consent
Exclusion Criteria
- dependence on drug other than marijuana
- pregnant, breast feeding, or planning to become pregnant within the next 3 months
- currently seeking treatment for cannabis-related problems or otherwise trying to reduce use
- use of cannabis under the guidance of a physician for a medical disorder
- unstable or uncontrolled cardiovascular disease (e.g., hypertension, angina)
- allergy to study medication
Data sourced from ClinicalTrials.gov (NCT00893074). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.